drugset / Trial / NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NaSingle-groupOpen-labelTreatment
Summary
The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2028-10-31
- Completion
- 2028-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Vinblastine | Small molecule | — | — |